Kyntra Bio Inc. (KYNB) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, KYNB scores 32 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows:

• Fundamental Cash Engine (4 / 20): Per the RQD rating, ROIC is -35% and FCF yield is 0%. This is the weakest pillar, indicating the business is not currently generating returns on capital or free cash flow to shareholders.
• Whale 13F Flow (3 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the lowest-scoring pillar, suggesting limited supportive institutional signal in the source data.
• Insider Conviction (7 / 20): Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The score is weak, and the source data does not detail the direction of individual trades beyond the news wire.
• Macro Regime Fit (6 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity noted. This pillar gives no particular defensive or regime-driven advantage.
• Forensic Balance Sheet (12 / 20): Per the RQD rating, Altman Z is 2.5, Piotroski F is 4/9, and Debt/Equity is 0.5. This is the strongest pillar, but still only moderate.

For a prospective investor, the pillar profile points to a company whose core economics are currently negative, with thin institutional and insider support. The forensic balance sheet is the main mitigating factor, but it does not offset weak cash generation. The grade reflects a risk-dominant picture; the analysis is educational and not personalized financial advice.

Per the SEC financials, revenue declined from $46.8M (FY 2023) to $29.6M (FY 2024) to $6.4M (FY 2025), while operating losses narrowed from $-322.7M to $-45.9M over the same span. Per the market data, operating margin is -60% and net margin is 68%; the FY 2025 net income figure of $183.5M sits far above its operating loss and is not explained in the source data. Per the RQD rating, ROIC is -35%, and the forensic balance sheet metrics are Altman Z 2.5 and Piotroski F 4/9 with Debt/Equity 0.5. Debt figures are Not available in source data for the reported periods.

Per the recent news wire, the dominant catalysts are governance and listing-related:

• Multiple reports cover a Nasdaq delisting notice and a company appeal of the listing decision, flagged as yellow-light market wire items.
• Multiple outlets report that Maxim initiated coverage with a Buy rating and a $35 price target, which stands sharply above the current price of $4.65 and should be weighed against the delisting risk.
• A report notes a director received 14,000 stock options at a $6.50 exercise price.

Risk watch items: the delisting notice and appeal status, the wide gap between the Maxim target and the current price, and the revenue decline. The Butterfly supply-chain graph reports no proprietary signals or links.

• What is the outcome of the Nasdaq delisting appeal, and what is the timeline for a decision?
• What drove the FY 2025 net income of $183.5M when operating income was $-45.9M, and is this a one-time item?
• What is the composition of total debt, given that debt is N/A across all reported periods?
• What are the company's specific products, approved indications, and revenue sources behind the declining top line?
• Is the Maxim $35 price target supported by a documented basis, and how does it reconcile with the $4.65 price?